Author: Alina Salganicoff
Published: November 3, 2026
The ongoing dialogue surrounding the state of women’s health research in the United States has once again brought to light a familiar historical pattern. In a recent column published in the prominent scientific journal Nature, Alina Salganicoff, a leading expert and Vice President and Director for Women’s Health Policy at KFF, reflects on a recurring theme in federal health policy: a modern "déjà vu moment" for women’s health research.
Salganicoff’s commentary looks back at previous administrative initiatives aimed at overhauling and elevating research into women’s health—efforts that, despite high hopes and initial momentum, ultimately fell short of fulfilling their long-term promise. By examining the historical barriers that have stalled past reforms, the commentary bridges the gap between past policy shortcomings and contemporary efforts to reshape the national research agenda.
At the center of these contemporary efforts are the formal recommendations put forth by a congressionally mandated committee organized under the National Academies of Sciences, Engineering, and Medicine (NASEM). Salganicoff, who co-chaired this distinguished NASEM committee, highlights its comprehensive roadmap designed to fundamentally improve how the National Institutes of Health (NIH) approach, fund, and prioritize women’s health research.
Examining the Historical Context of Federal Policy Shortfalls
For decades, the landscape of biomedical research in the United States has grappled with systemic gaps in how female physiology is studied, funded, and understood. Historically, clinical research relied heavily on male subjects under the assumption that findings could be universally applied across sexes, ignoring crucial biological differences in disease presentation, progression, and pharmacological response.
Over the years, various U.S. administrations have attempted to correct these historical imbalances. Executive branches and legislative bodies have introduced numerous initiatives, policy frameworks, and targeted funding streams designed to mandate the inclusion of women in clinical trials and boost support for conditions that disproportionately or differently affect women.
However, as Salganicoff points out in her Nature column, these previous campaigns frequently lost momentum. Institutional inertia, inconsistent funding, a lack of enforcement mechanisms for inclusion guidelines, and shifting political priorities often diluted the impact of these initiatives. Consequently, critical areas of women’s health—ranging from autoimmune diseases and cardiovascular conditions to reproductive health and beyond—have continued to experience persistent knowledge gaps and underfunding relative to their public health burden.
A New Path Forward: The NASEM Committee Recommendations
Recognizing that past administrative pushes have often failed to produce permanent structural transformation, Congress mandated the creation of a specialized National Academies of Sciences, Engineering, and Medicine committee to conduct a rigorous, independent evaluation of the NIH’s structures and practices regarding women’s health research.
Co-chaired by Salganicoff, the NASEM committee was tasked with developing actionable, evidence-based recommendations to ensure that future research endeavors avoid the pitfalls of the past. The committee’s report outlines strategic reforms aimed at embedding sex and gender considerations deeply into the foundational fabric of the NIH’s scientific portfolio.
Among its core recommendations, the committee emphasizes the necessity of strengthening institutional accountability, enhancing coordination across various NIH institutes and centers, and establishing robust mechanisms to monitor compliance with inclusion policies. Rather than treating women’s health as a niche or supplementary category of research, the NASEM framework advocates for a systematic integration of sex-as-a-biological-variable principles across all fields of biomedical science.
The Broader Landscape of Women’s Health Policy and Federal Budgets
The release of the Nature column and the dissemination of the NASEM committee’s findings arrive at a critical juncture for federal health policy, the Department of Health and Human Services (HHS), and the federal budget. Policymakers, researchers, and advocacy groups continue to scrutinize how federal dollars are allocated and whether public health agencies are adequately equipped to meet the comprehensive health needs of the population.
Discussions surrounding federal budget allocations for health agencies frequently intersect with broader policy priorities. Observers note that translating committee recommendations into tangible, long-lasting policy changes will require sustained legislative oversight and active collaboration between the scientific community, federal agencies, and executive leadership. Without dedicated, protected funding streams and structural oversight, there is a risk that current enthusiasm for women’s health reform could mirror the historical cycles of high-profile promises followed by underwhelming institutional follow-through.
Related Issues in Women’s Health Information and Access
The challenges inherent in women’s health research directly influence the broader ecosystem of health information, clinical care, and patient resources available to the public. When clinical data and research foundations are incomplete, the downstream effects manifest in how women access health information online, navigate trusted medical resources, and make informed decisions regarding their care.
Parallel policy discussions and research analyses by organizations like KFF frequently explore these interconnected domains. From examining how women seek and evaluate health information across digital platforms to assessing access to specialized services such as fertility care and reproductive health resources, the overarching theme remains consistent: the quality, accuracy, and availability of clinical care depend fundamentally on robust foundational research.
As the scientific community and federal policymakers digest the recommendations from the NASEM committee and weigh the lessons of past administrations, the focus remains squarely on accountability and implementation. Whether this current wave of attention will permanently alter the trajectory of federally funded research—or become another chapter in a history of unrealized potential—will depend heavily on the sustained commitment of institutional leaders and lawmakers in the months and years ahead.
